Literature DB >> 23793713

UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82.

A J Hayes1, J Leal, A M Gray, R R Holman, P M Clarke.   

Abstract

AIMS/HYPOTHESIS: The aim of this project was to build a new version of the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS-OM1), a patient-level simulation tool for predicting lifetime health outcomes of people with type 2 diabetes mellitus.
METHODS: Data from 5,102 UKPDS patients from the 20 year trial and the 4,031 survivors entering the 10 year post-trial monitoring period were used to derive parametric proportional hazards models predicting absolute risk of diabetes complications and death. We re-estimated the seven original event equations and estimated new equations for diabetic ulcer and some second events. The additional data permitted inclusion of new risk factor predictors such as estimated GFR. We also developed four new equations for all-cause mortality. Internal validation of model predictions of cumulative incidence of all events and death was carried out and a contemporary patient-level dataset was used to compare 10 year predictions from the original and the new models.
RESULTS: Model equations were based on a median 17.6 years of follow-up and up to 89,760 patient-years of data, providing double the number of events, greater precision and a larger number of significant covariates. The new model, UKPDS-OM2, is internally valid over 25 years and predicts event rates for complications, which are lower than those from the existing model. CONCLUSIONS/
INTERPRETATION: The new UKPDS-OM2 has significant advantages over the existing model, as it captures more outcomes, is based on longer follow-up data, and more comprehensively captures the progression of diabetes. Its use will permit detailed and reliable lifetime simulations of key health outcomes in people with type 2 diabetes mellitus.

Entities:  

Mesh:

Year:  2013        PMID: 23793713     DOI: 10.1007/s00125-013-2940-y

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  24 in total

Review 1.  Guidelines for computer modeling of diabetes and its complications.

Authors: 
Journal:  Diabetes Care       Date:  2004-09       Impact factor: 19.112

2.  Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.

Authors:  Alan S Go; Jingrong Yang; Lynn M Ackerson; Krista Lepper; Sean Robbins; Barry M Massie; Michael G Shlipak
Journal:  Circulation       Date:  2006-06-05       Impact factor: 29.690

Review 3.  Diabetes in Asia: epidemiology, risk factors, and pathophysiology.

Authors:  Juliana C N Chan; Vasanti Malik; Weiping Jia; Takashi Kadowaki; Chittaranjan S Yajnik; Kun-Ho Yoon; Frank B Hu
Journal:  JAMA       Date:  2009-05-27       Impact factor: 56.272

4.  Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6.

Authors:  Andrew H Briggs; Milton C Weinstein; Elisabeth A L Fenwick; Jonathan Karnon; Mark J Sculpher; A David Paltiel
Journal:  Value Health       Date:  2012 Sep-Oct       Impact factor: 5.725

5.  Transparency and reproducible research in modeling: why we need it and how to get there.

Authors:  Crystal M Smith-Spangler
Journal:  Med Decis Making       Date:  2012 Sep-Oct       Impact factor: 2.583

6.  Assessing the impact of visual acuity on quality of life in individuals with type 2 diabetes using the short form-36.

Authors:  Philip M Clarke; Judit Simon; Carole A Cull; Rury R Holman
Journal:  Diabetes Care       Date:  2006-07       Impact factor: 19.112

7.  A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).

Authors:  P M Clarke; A M Gray; A Briggs; A J Farmer; P Fenn; R J Stevens; D R Matthews; I M Stratton; R R Holman
Journal:  Diabetologia       Date:  2004-10-27       Impact factor: 10.122

8.  Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial.

Authors:  Judit Simon; Alastair Gray; Philip Clarke; Alisha Wade; Andrew Neil; Andrew Farmer
Journal:  BMJ       Date:  2008-04-17

9.  White blood cell count is associated with macro- and microvascular complications in chinese patients with type 2 diabetes.

Authors:  Peter C Tong; Ka-Fai Lee; Wing-Yee So; Margaret H Ng; Wing-Bun Chan; Matthew K Lo; Norman N Chan; Juliana C Chan
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

Review 10.  Validation of population-based disease simulation models: a review of concepts and methods.

Authors:  Jacek A Kopec; Philippe Finès; Douglas G Manuel; David L Buckeridge; William M Flanagan; Jillian Oderkirk; Michal Abrahamowicz; Samuel Harper; Behnam Sharif; Anya Okhmatovskaia; Eric C Sayre; M Mushfiqur Rahman; Michael C Wolfson
Journal:  BMC Public Health       Date:  2010-11-18       Impact factor: 3.295

View more
  133 in total

Review 1.  A Comprehensive Review of Novel Drug-Disease Models in Diabetes Drug Development.

Authors:  Puneet Gaitonde; Parag Garhyan; Catharina Link; Jenny Y Chien; Mirjam N Trame; Stephan Schmidt
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

2.  Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting.

Authors:  Melanie J Davies; Divina Glah; Barrie Chubb; Gerasimos Konidaris; Phil McEwan
Journal:  Pharmacoeconomics       Date:  2016-09       Impact factor: 4.981

3.  Cost-Effectiveness of Orthogeriatric and Fracture Liaison Service Models of Care for Hip Fracture Patients: A Population-Based Study.

Authors:  Jose Leal; Alastair M Gray; Samuel Hawley; Daniel Prieto-Alhambra; Antonella Delmestri; Nigel K Arden; Cyrus Cooper; M Kassim Javaid; Andrew Judge
Journal:  J Bone Miner Res       Date:  2016-11-01       Impact factor: 6.741

4.  The Impact of Biomarker Screening and Cascade Genetic Testing on the Cost-Effectiveness of MODY Genetic Testing.

Authors:  Matthew S GoodSmith; M Reza Skandari; Elbert S Huang; Rochelle N Naylor
Journal:  Diabetes Care       Date:  2019-09-26       Impact factor: 19.112

5.  Matching Microsimulation Risk Factor Correlations to Cross-sectional Data: The Shortest Distance Method.

Authors:  Sze-Chuan Suen; Jeremy D Goldhaber-Fiebert; Sanjay Basu
Journal:  Med Decis Making       Date:  2017-11-29       Impact factor: 2.583

6.  Event and Cost Offsets of Switching 20% of the Type 1 Diabetes Population in Germany From Multiple Daily Injections to Continuous Subcutaneous Insulin Infusion: A 4-Year Simulation Model.

Authors:  York Francis Zöllner; Ralph Ziegler; Magnus Stüve; Julia Krumreich; Marion Schauf
Journal:  J Diabetes Sci Technol       Date:  2016-08-22

7.  Replicating Health Economic Models: Firm Foundations or a House of Cards?

Authors:  Inigo Bermejo; Paul Tappenden; Ji-Hee Youn
Journal:  Pharmacoeconomics       Date:  2017-11       Impact factor: 4.981

8.  Modeling Treatment Sequences in Pharmacoeconomic Models.

Authors:  Ying Zheng; Feng Pan; Sonja Sorensen
Journal:  Pharmacoeconomics       Date:  2017-01       Impact factor: 4.981

9.  Prognostic value of plasma MR-proADM vs NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study.

Authors:  Mathilde Fraty; Gilberto Velho; Elise Gand; Fréderic Fumeron; Stéphanie Ragot; Philippe Sosner; Kamel Mohammedi; Barnabas Gellen; Pierre-Jean Saulnier; Jean-Michel Halimi; David Montaigne; Grégory Ducrocq; Michaela Rehman; Michel Marre; Ronan Roussel; Samy Hadjadj
Journal:  Diabetologia       Date:  2018-09-19       Impact factor: 10.122

10.  Design and participant characteristics for a randomized effectiveness trial of an intensive lifestyle intervention to reduce cardiovascular risk in adults with type 2 diabetes: The I-D-HEALTH study.

Authors:  David T Liss; Emily A Finch; Dyanna L Gregory; Andrew Cooper; Ronald T Ackermann
Journal:  Contemp Clin Trials       Date:  2015-12-02       Impact factor: 2.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.